Deep Freeze: Innovations in Lyophilization - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Deep Freeze: Innovations in Lyophilization
By reducing cycle time and implementing quality-by-design inspired engineering, advanced lyophilization systems are driving the industry toward greater efficiency and control.

Pharmaceutical Technology
Volume 33, Issue 4, pp. 36-42

Although lyophilization as a practice of preservation has existed for many years, perfecting the science continues to be a highly sought after objective of parenteral drug manufacturers. The strong push for increasing the number of protein-based therapeutics and other injectable products through development has contributed to the need for leaner, more cost-efficient freeze-drying methods without compromising quality. Boosting quality involves identifying vulnerable critical process parameters. To address the needs for safety, reduced risk, and better control, industry has designed solutions for use in the three areas of the lyophilization process well known to be highly susceptible: stopper placement, lyophilizer loading and unloading, and freezing.

PAT and QbD: drivers of innovation

The US Food and Drug Administration's efforts to cultivate better understanding and control into many sectors of the process development cycle, including lyophilization, are evident.

"A lot of the emphasis has been spent in the past couple of years on identifying the limits of the freeze-drying process," says Heinrich Meintrup, managing director of GEA Pharma Systems (Hurth, Germany). "The basis is having to identify the weak points. The efforts in lyophilization are going toward trying to get a closer understanding of what is going on in a big installation, across all the vials, and within individual vials. How can we eliminate variability of the results in individual vials and how do we improve the design of the equipment to reduce this variability? It comes from better capturing the process conditions and understanding."

Solutions for monitoring lyophilizer shelf temperature and chamber pressure over time has involved the implementation of radio-frequency transitioned data, process analytical technology (PAT)-inspired wireless sensors, manometric temperature measurement approaches, and "smart" vials (1). Other methods include barometric temperature measurement (BTM).

This approach measures the broad temperature barometrically without the need for placing a real sensor. The strategy is especially advantageous in fully automated systems in which it may be difficult to first place a real sensor in a vial and then downstream to remove this single vial.

"It is a method that is based on physics ... now integrated into the control system as part of the PAT initiative," says Meintrup. "If you look at what has been driven by PAT, so clearly it is about temperature distribution, having clear information about what stage the process is at any time inside of the freeze dryer. Because it is a big chamber closed under vacuum conditions, you cannot take a sample, there is nothing you can see from outside other than frozen vials." Measuring equipment added to freeze dryers provides a level of understanding of what is going on in the chamber as well as some justification of the particular stage of the freeze-drying process.

Shrinking the cleanroom

For contract facilities or clinical-trial material processes, innovative solutions must take place within a limited space. These facilities may not have the resources to set up and maintain large expensive cleanrooms and must rely on other means to control contamination at critical points. One of these process points is stopper placement. Traditionally, sterile split-stoppers are placed only part way down the vials, allowing vapor to escape during lyophilization. After lyophilization, under vacuum or atmospheric conditions, the stopper is pushed into its final position by the freeze-dryer shelves to seal the vials. However, industry researchers point out that the semi-open vials are at risk of being exposed to potential contaminants.

At the 2008 American Association of Pharmaceutical Scientists annual meeting, W.L. Gore and Associates of Elkton, MD, introduced a bicomponent material technology to seal vials off from external environments (Gore Lyoguard vial isolator). The system incorporates a microporous vent to protect the product inside the vial, which effectively shrinks the cleanroom to a one-vial size. The unit provides a level of filtration such that the product can be freeze-dried through the membrane.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here